AC IMMUNE SA

AC IMMUNE SA

AC Immune SA, a clinical stage biopharmaceutical company, discovers, designs, and develops medicines and diagnostic products for the prevention and treatment of neurodegenerative diseases associated with protein misfolding. Its SupraAntigen and Morphomer platforms are designed to generate vaccines, antibodies, and small molecules, which selectively interact with misfolded proteins that are common in a range of neurodegenerative diseases. The company is developing Crenezumab, a humanized, conform... ation-specific monoclonal antibody, which is in Phase II clinical prevention trial for the treatment of Alzheimer's disease (AD). It is also developing ACI-24, an anti-Abeta vaccine candidate that is in Phase II clinical study for AD, as well as completed Phase Ib clinical study for Down syndrome; ACI-35, an anti-Tau vaccine candidate that has completed Phase Ib clinical study; and Tau- positron emission tomography (PET) imaging tracer, which is in Phase II clinical study. In addition, the company is researching and developing small molecule Tau aggregation inhibitors for AD and NeuroOrphan indications. Further, it has discovery and preclinical stage molecules targeting range of neurodegenerative diseases, which include diagnostics targeting TDP-43, alpha-synuclein, and NLRP3. The company has license agreements and collaborations with Genentech, Inc.; Biogen International GmbH; Janssen Pharmaceuticals, Inc.; Life Molecular Imaging SA; Eli Lilly and Company; and WuXi Biologics. AC Immune SA was incorporated in 2003 and is headquartered in Lausanne, Switzerland.

AC Immune SA_logo

Industry:
Company

Founded:
2/13/2003

Address:
Building B, Lausanne, Switzerland Zipcode 1015

Country:
Switzerland

Phone:
41 21 345 91 21

Market Cap:
499.46M
Total Revenue:
15.43M
Total Assets:
238.74M
Total Cash:
160.89M

Founder: Andrea Pfeifer


Key Executives
Name Title Pay Year Born
Dr. Andrea Pfeifer Co-Founder, CEO & Director 1,131,249$ 1957(63 years old)
Mr. Joerg Hornstein Chief Financial Officer N/A 1978(42 years old)
Mr. Piergiorgio Donati Chief Technical Operations Officer N/A 1971(49 years old)
Dr. Marie Kosco-Vilbois Chief Scientific Officer N/A 1958(62 years old)
Mr. Jean-Fabien Monin Chief Admin. Officer N/A 1971(49 years old)
Joshua Drumm Ph.D. Head of Investor Relations N/A N/A
Mr. Alexandre Caratsch Gen. Counsel N/A 1966(54 years old)
Judith Moore Global Head of Communications N/A N/A
Mr. Gautam Maitra Fil. Lic Head of Regulatory & External Affairs and Sr. Expert N/A N/A
Dr. Maria Pihlgren Ph.D. Head of Biology N/A N/A



Financial & Stock
Exchange NasdaqGS. Currency in USD. Market state CLOSED
According to AC Immune SA's financial reports the company's revenue in 2020 were 15.43M an increase(-86.36%) over the years 2019 revenue that were of 110.46M. In 2020 the company's total earnings were -61.92M while total earnings in 2019 were 45.44M(-235.56%).
Company's stock symbol is ACIU. Lastest price : 6.87. Total volume :189.21k Click reload if you want to check the lastest price on market!!!


Site Inspections: http://www.acimmune.com

  • Host name: h2web102.infomaniak.ch
  • IP address: 83.166.138.60
  • Location: Switzerland
  • Latitude: 47.1449
  • Longitude: 8.1551
  • Timezone: Europe/Zurich

Loading ...
Loading ...


More informations about "AC Immune SA" on Search Engine

AC Immune

Acimmune.com At AC Immune, we are passionate about making a difference in the lives of people affected by Alzheimer’s and other neurodegenerative diseases. Our goal is to become the global leader in precision medicine of neurodegenerative diseases that are one of the biggest challenges facing society today and future generations.

AC Immune

Acimmune.com AC Immune | AC Immune's robust pipeline

AC Immune

Acimmune.com AC Immune’s leadership team combines a proven track record in entrepreneurial …

AC Immune

Acimmune.com Contact information. AC Immune SA EPFL Innovation Park Building B 1015 Lausanne …

AC Immune

Acimmune.com AC Immune’s therapeutic and diagnostic agents are at the forefront of fighting …

AC Immune

Acimmune.com AC Immune and Genentech have been partners for a decade: In 2006, AC Immune …

AC Immune

Acimmune.com AC Immune | Career opportunities. AC Immune biopharmaceutical company developing …

AC Immune

Acimmune.com AC Immune | AC Immune Key Opinion Leader (KOL) Breakfast

AC Immune

Acimmune.com Featured Speakers: Margaret Chan, Formerly WHO, Haruo Naito, Eisai Co. Ltd, Andrea …

AC Immune

Acimmune.com In response, AC Immune has developed a five point Roadmap to Successful Therapies for …

AC Immune SA (ACIU) Stock Price, News, Quote & History

Finance.yahoo.com About AC Immune SA AC Immune SA is clinical-stage biopharmaceutical company that aims to become a global leader in precision medicine for neurodegenerative diseases, including Alzheimer’s disease,...

ACIU Stock Price | AC Immune S.A. Stock Quote (U.S)

Marketwatch.com Mar 26, 2021 · AC Immune S.A. AC Immune SA engages in the discovery and development of therapeutic and diagnostic products for neurodegenerative diseases.

ACIU - AC Immune SA • BioPharmCatalyst

Biopharmcatalyst.com Sep 23, 2016 · LAUSANNE, Switzerland, March 09, 2021 (GLOBE NEWSWIRE) -- AC Immune SA (NASDAQ: ACIU), a Swiss-based, clinical-stage biopharmaceutical company with a broad pipeline focused on neurodegenerative diseases, today outlined new preclinical data that will be presented at the 15 th International Conference on Alzheimer's…

Why AC Immune Stock Is Crashing Today | The Motley Fool

Fool.com Sep 23, 2020 · Shares of the Swiss biotech AC Immune (NASDAQ:ACIU) lost over 42% of their value in pre-market trading Wednesday morning. The biotech's stock is …

Events | AC Immune SA

Ir.acimmune.com 32 rows · Featured Speakers: Margaret Chan, Formerly WHO, Haruo Naito, Eisai Co. Ltd, Andrea …

AC IMMUNE SA : Shareholders Board Members Managers and

Marketscreener.com AC Immune SA is a Switzerland-based clinical-stage biopharmaceutical company. The Company focuses on precision medicine for neurodegenerative diseases. It designs, discovers and develops therapeutic, as well as diagnostic products for prevention, diagnosis and treatment of diseases caused by misfolding proteins.

AC Immune Advances phospho-Tau Alzheimer’s Vaccine in

Ir.acimmune.com Jul 16, 2020 · AC Immune SA is a Nasdaq-listed clinical-stage biopharmaceutical company, which aims to become a global leader in precision medicine for neurodegenerative diseases.

AC Immune SA Common Stock (ACIU) Stock Quotes | Nasdaq

Nasdaq.com AC Immune SA Common Stock (ACIU) Stock Quotes - Nasdaq offers stock quotes & market activity data for US and global markets.

AC Immune to Present New Data from Alpha-Synuclein and TDP

Globenewswire.com Feb 24, 2021 · AC Immune SA is a Nasdaq-listed clinical-stage biopharmaceutical company, which aims to become a global leader in precision medicine for neurodegenerative diseases.

AC Immune SA (ACIU) Latest Stock News & Headlines - Yahoo

Finance.yahoo.com Price Action Company's 52-week high was at $13.00 Company's 52-week low was at $4.42 Price action over last quarter: Up 58.76% Company Profile AC Immune SA is a clinical-stage biopharmaceutical ...

AC Immune Appoints Experienced Biotech and Investment

Globenewswire.com Mar 31, 2021 · AC Immune SA is clinical-stage biopharmaceutical company that aims to become a global leader in precision medicine for neurodegenerative diseases, …

AC IMMUNE SA : ACIU Stock Price | CH0329023102

Marketscreener.com AC Immune SA is a Switzerland-based clinical-stage biopharmaceutical company. The Company focuses on precision medicine for neurodegenerative diseases. It designs, discovers and develops therapeutic, as well as diagnostic products for prevention, diagnosis and treatment of diseases caused by misfolding proteins.

@AC_Immune_SA | Twitter

Twitter.com The latest tweets from @AC_Immune_SA

ACIU: AC Immune SA - Stock Price, Quote and News - CNBC

Cnbc.com AC Immune SA is a Switzerland-based clinical-stage biopharmaceutical company. The Company focuses on precision medicine for neurodegenerative diseases. It designs, discovers and develops ...

AC Immune | LinkedIn

Linkedin.com AC Immune | 6,119 followers on LinkedIn. We shape the future of neurodegeneration by discovering and developing breakthrough therapies through pioneering science | AC Immune is a clinical-stage ...

Extraordinary General Meeting | AC Immune SA

Ir.acimmune.com The Investor Relations website contains information about AC Immune SA's business for stockholders, potential investors, and financial analysts.

Things Look Grim For AC Immune SA (NASDAQ:ACIU) After

Nasdaq.com Mar 28, 2021 · Market forces rained on the parade of AC Immune SA (NASDAQ:ACIU) shareholders today, when the analysts downgraded their forecasts for this year. Revenue and earnings per share (EPS) forecasts were...

SEC Filing | AC Immune SA

Ir.acimmune.com AC IMMUNE SA (Exact name of Registrant as specified in its charter) Switzerland (Jurisdiction of incorporation) EPFL INNOVATION PARK Building B 1015 Lausanne Switzerland (Address of principal executive offices) Andrea Pfeifer Tel: +41 21 345 91 21 EPFL INNOVATION PARK Building B

AC Immune Explodes 56% In Pre-Market On Alzheimer Study

Finance.yahoo.com Jul 16, 2020 · Prof. Andrea Pfeifer, CEO of AC Immune SA, commented: “The fact that ACI-35.030 shows encouraging safety and immunogenicity at the lowest dose …

Here's Why AC Immune Jumped Higher Today | The Motley Fool

Fool.com Jul 16, 2020 · AC Immune SA NASDAQ: ACIU $7.34 down $0.45 (-5.78%) JNJ. Johnson & Johnson NYSE: JNJ $165.01 down $-1.03 (-0.62%) Related Articles. Why AC Immune Stock Surged Today; Why AC Immune Stock Is ...

Ac Immune Sa - ACIU - Stock Price Today - Zacks

Zacks.com AC Immune SA is a biopharmaceutical company. It develops, discover and design novel, proprietary medicines for prevention, diagnosis and treatment of neurodegenerative diseases.

Why AC Immune Stock Surged Today | The Motley Fool

Fool.com Feb 12, 2021 · AC Immune SA NASDAQ: ACIU $7.01 down $0.08 (-1.13%) Related Articles. Why AC Immune Stock Is Crashing Today; Here's Why AC Immune Jumped Higher Today; Why AC Immune SA Is Imploding; Here's Why AC ...

Why AC Immune SA Is Imploding | The Motley Fool

Fool.com Jan 30, 2019 · AC Immune SA NASDAQ: ACIU $7.09 down $0.53 (-6.96%) RHHBY. Roche Holding AG OTC: RHHBY $40.86 down $0.59 (-1.42%) Related Articles. Why AC Immune Stock Surged Today; Why AC Immune Stock Is ...

ACIU:NASDAQ GM Stock Quote - AC Immune SA - Bloomberg …

Bloomberg.com About AC Immune SA AC Immune SA operates as a biopharmaceutical company. The Company discovers, designs, and develops medicines for prevention, diagnosis, and treatment of neurodegenerative ...

AC Immune Initiates IND-Enabling Studies for First-in

Globenewswire.com Aug 03, 2020 · AC Immune SA is a Nasdaq-listed clinical-stage biopharmaceutical company, which aims to become a global leader in precision medicine for neurodegenerative diseases. The …

AC Immune SA Company Profile | Lausanne, VAUD, Switzerland

Dnb.com AC Immune SA has 50 employees at this location and generates $109.75 million in sales (USD). D&B Hoovers provides sales leads and sales intelligence data on over 120 million companies like AC Immune SA around the world, including contacts, financials, and competitor information.

AC Immune SA - Company Profile and News - Bloomberg Markets

Bloomberg.com AC Immune SA operates as a biopharmaceutical company. The Company discovers, designs, and develops medicines for prevention, diagnosis, and treatment of …

AC Immune SA (ACIU) Company Profile & Facts - Yahoo Finance

Finance.yahoo.com AC Immune SA, a clinical stage biopharmaceutical company, discovers, designs, and develops medicines and diagnostic products for the prevention and treatment of neurodegenerative diseases ...

AC Immune SA (NASDAQ:ACIU): Blank Check On Growth

Stocksregister.com Apr 03, 2021 · AC Immune SA’s market cap currently stands at around $568.6 Million, with investors looking forward to this quarter’s earnings report slated for May 03, 2021- May 07, 2021. The company has a Forward Dividend ratio of 0, with its dividend yield at 0%.

Earnings Update: AC Immune SA (NASDAQ:ACIU) Just Reported

Nasdaq.com Mar 25, 2021 · AC Immune SA (NASDAQ:ACIU) shareholders are probably feeling a little disappointed, since its shares fell 2.4% to US$7.70 in the week after its …

AC Immune Hosts Investor Webinar Highlighting the Power of

Globenewswire.com Mar 31, 2021 · AC Immune SA is clinical-stage biopharmaceutical company that aims to become a global leader in precision medicine for neurodegenerative diseases, …

Analysts Just Shipped A Meaningful Upgrade To Their AC

Nasdaq.com Jan 24, 2021 · Shareholders in AC Immune SA (NASDAQ:ACIU) may be thrilled to learn that the analysts have just delivered a major upgrade to their near-term forecasts. The consensus statutory numbers for both ...

Ac Immune Sa Stock Quote: ACIU Stock News, Quotes

Research.investors.com Jun 01, 2020 · ACIU, Ac Immune Sa - Stock quote performance, technical chart analysis, SmartSelect Ratings, Group Leaders and the latest company headlines

AC Immune SA (ACIU) Quote - XNAS | Morningstar

Morningstar.com AC Immune SA is a clinical-stage biopharmaceutical company that focuses on neurodegenerative diseases. The company uses its proprietary technology platforms to …

ACIU: AC Immune SA - Financial Overview - Zacks Investment

Zacks.com Apr 09, 2021 · View ACIU: AC Immune SAinvestment & stock information. Get the latest ACIU: AC Immune SA detailed stock quotes, stock data, Real-Time ECN, charts, stats and more..

AC Immune SA (ACIU) Stock Forum & Discussion - Yahoo Finance

Finance.yahoo.com Douglas Williams, Ph.D., Chairman of AC Immune SA, commented: "The wealth of experience and credibility Dr. Colowick brings to AC Immune's Board will be invaluable as we continue to …

AC Immune SA (ACIU) Stock Message Board - InvestorsHub

Investorshub.advfn.com Feb 11, 2021 · AC Immune’s therapeutic and diagnostic agents are at the forefront of fighting against one of the world’s greatest healthcare challenges – the need to develop reliable and accurate diagnostics and disease modifying treatments to improve the lives of patients suffering from Alzheimer’s and other neurodegenerative diseases.

ACIU AC Immune SA stock - finscreener.org

Finscreener.org AC Immune SA. AC Immune SA is a clinical-stage biopharmaceutical company that focuses on neurodegenerative diseases. The company uses its proprietary technology platforms to discover, design, and develop novel proprietary small molecules, antibodies, and vaccines for prevention, diagnosis, and treatment of neurodegenerative diseases associated with protein misfolding.

AC Immune SA (ACIU : NASDAQ) Stock Price & News - Google

Google.com Get the latest AC Immune SA (ACIU) real-time quote, historical performance, charts, and other financial information to help you make more informed trading and investment decisions.

AC Immune SA (Form: 6-K, Received: 08/08/2018 06:11:10)

Content.edgar-online.com AC Immune SA (the “Company,” or “AC Immune,” “ACI,” “we,” “our,” “ours,” “us”) is a clinical stage biopharmaceutical company leveraging our two proprietary technology platforms to discover, design and develop novel, proprietary medicines for prevention, diagnosis and treatment of neurodegenerative diseases associated ...

AC Immune SA - Stock Price History | ACIU | MacroTrends

Macrotrends.net Historical daily share price chart and data for AC Immune SA since 2021 adjusted for splits. The latest closing stock price for AC Immune SA as of February 26, 2021 is 7.59.. The all-time high AC Immune SA stock closing price was 19.30 on September 28, 2016.; The AC Immune SA 52-week high stock price is 13.00, which is 71.3% above the current share price.

ACIU: AC Immune SA - Earnings News & Analysis - Zacks

Zacks.com ACIU: AC Immune SA - Earnings Announcements. Stay up to date with lastest Earnings Announcements for AC Immune SA from Zacks Investment Research